Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.95), $0.06 worse than the analyst estimate of ($0.89). Revenue for the quarter came in at $22.2 million versus the consensus estimate of $22.25 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.